Regarding effects on the tumor microenvironment, on one hand, idelalisib increases the CD8+ T-cell response and inhibits Treg-cells; on the other hand, it decreases antibody-dependent phagocytosis by macrophages [150,151]. The gene discussed is CD8A; the disease is neoplasm.